Fique off-line com o app Player FM !
Homologous Recombination Repair (HRR) Testing and Targeted Therapy in Prostate Cancer
Manage episode 409274058 series 3256997
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
- Rationale for targeting PARP in prostate cancer with ARI combinations
- Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
- FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
- Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
- Tips for optimal coordination between pathology and medical oncology
Presenters:
Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington
Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington
Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.
Link to full program:
https://bit.ly/3PFagxb
185 episódios
Manage episode 409274058 series 3256997
In this episode, Colin C. Pritchard, MD, PhD, a pathologist, and Heather H. Cheng, MD, PhD, a medical oncologist, discuss optimal biomarker testing to guide treatment decisions in advanced prostate cancer, with topics including:
- Rationale for targeting PARP in prostate cancer with ARI combinations
- Study design nuances and findings from key randomized phase III clinical trials evaluating combination therapy with a PARP inhibitor and ARI, including PROpel, MAGNITUDE, and TALAPRO-2
- FDA approvals of combination therapy with a PARP inhibitor and ARI, including a comparison of populations based on mutations
- Optimal biomarker testing for gene mutations in homologous recombination and mismatch repair pathways
- Tips for optimal coordination between pathology and medical oncology
Presenters:
Heather H. Cheng, MD, PhD
Associate Professor
Department of Medicine
Division of Hematology and Oncology
Attending Physician
Department of Genitourinary Medical Oncology
Fred Hutchinson Cancer Center
Seattle, Washington
Colin C. Pritchard, MD, PhD
Co-Director
Genetics and Solid Tumors Laboratory
University of Washington Medical Center
Professor
Department of Laboratory Medicine and Pathology
University of Washington
Seattle, Washington
Content based on an online CME program supported by an independent educational grant from Pfizer, Inc.
Link to full program:
https://bit.ly/3PFagxb
185 episódios
Tüm bölümler
×Bem vindo ao Player FM!
O Player FM procura na web por podcasts de alta qualidade para você curtir agora mesmo. É o melhor app de podcast e funciona no Android, iPhone e web. Inscreva-se para sincronizar as assinaturas entre os dispositivos.